CHU Amiens
Amiens, 80054, France
Location status: Recruiting
NCT Number: NCT06373926
Annexin A2 (ANXA2), an endothelial cell receptor for plasminogen and tissue plasminogen activator, plays a pivotal role in regulation of fibrinolysis in vitro and in vivo and has been identified as a new autoantigen in antiphospholipid syndrome (APS). ANXA2 can exist as a monomer or a heterotetrameric complex with S100A10 protein. The aim of this study was to evaluate the cell membrane expression of ANXA2 on circulating monocytes in APS by flow cytometry. Several pathogenic mechanisms are involved in APS such as activation of endothelial cells, platelets and monocytes, inhibition of the natural anticoagulant protein C/protein S pathway, activation of the complement system and also impairment of fibrinolysis. Annexin A2 which hits binding partner S100A10, ANXA2 forms a cell surface complex that regulates generation of plasmin. ANXA2 is involved in the pathogenesis of APS-associated through several possible mechanisms. Human peripheral blood monocytes represent the major circulating ANXA2-expressing cell and ANXA2-mediated assembly of plasminogen and tissue activator of plasminogen (tPA) on monocyte/macrophages contributes to plasmin generation. Thus the investigators could suppose that decrease of cell membrane expression of ANXA2 on circulating monocytes represent a new pathogenic mechanism in APS.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Amiens, 80054, France
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
blood withdrawal
Time frame: 1 hour
Time frame: 1 hour
Time frame: 1 hour
Contact information is provided by the study sponsor or research team.
Centre Hospitalier Universitaire, Amiens
Other
Acronym: MONOCYTAN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07142239
Antiphospholipid Syndrome, Autoimmune Diseases
Al Khārjah, Kharga Oasis, Egypt
View Trial DetailsNCT07087912
Ankylosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
São Paulo, Brazil
View Trial DetailsNCT00482794
Antiphospholipid Syndrome, Autoimmune Diseases
Durham, North Carolina, United States
View Trial DetailsNCT04262492
Anticoagulants Causing Adverse Effects in Therapeutic Use, Antiphospholipid Syndrome
Nancy, France
View Trial Details